GBP/USD 1.372 EUR/GBP 0.858 GBP/JPY 197.381 EUR/USD 1.178 GBP/AUD 2.088 USD/JPY 143.817 USD/CAD 1.366 AUD/USD 0.657 CAD/JPY 105.319 EUR/CAD 1.608 GBP/CAD 1.874 AUD/CAD 0.897 AUD/JPY 94.512 AUD/NZD 1.080 EUR/AUD 1.792 GBP/USD 1.372 EUR/GBP 0.858 GBP/JPY 197.381 EUR/USD 1.178 GBP/AUD 2.088 USD/JPY 143.817 USD/CAD 1.366 AUD/USD 0.657 CAD/JPY 105.319 EUR/CAD 1.608 GBP/CAD 1.874 AUD/CAD 0.897 AUD/JPY 94.512 AUD/NZD 1.080 EUR/AUD 1.792
CURRENCY .wiki

Finance News – Glp

What is your interest today?

Quartz • Jun 27, 2025

The weight loss drug boom has barely begun. How big can it get?

The rising popularity of GLP-1 medications, including Ozempic, positions them to generate substantial revenue, potentially surpassing established blockbuster drugs like statins in...

Read Full Article →
City A.M. • Jun 24, 2025

Slim pickings: grocery sales down as Brits turn to weight-loss jabs

The increasing adoption of prescription medications for weight management is contributing to reduced grocery store revenues, as consumers adjust their purchasing habits beyond typi...

Read Full Article →
Quartz • May 30, 2025

How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...

Read Full Article →
The Guardian – Business • May 22, 2025

WeightWatchers scraps business model to team up with anti-obesity drugs provider

The collaboration with a pharmaceutical company offering GLP-1 treatments represents a strategic move for the brand to diversify revenue streams and address declining market compet...

Read Full Article →
MarketWatch Top Stories • May 14, 2025

This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent

The collaboration between Novo Nordisk and Septerna is expected to enhance their pipeline in obesity and diabetes therapies, potentially increasing market value and investor confid...

Read Full Article →
Quartz • May 13, 2025

Weight loss drugs are squeezing the food industry

The rapid success of GLP-1 medications is driving substantial revenue growth for pharmaceutical companies while simultaneously reducing consumer spending and demand within the food...

Read Full Article →
Quartz • May 07, 2025

Weight Watchers goes bankrupt even as it tries to ride the Ozempic boom

WeightWatchers has filed for bankruptcy due to over $1 billion in debt, aiming to restructure its finances while shifting focus toward weight loss medications such as GLP-1 treatme...

Read Full Article →
Quartz • Apr 30, 2025

Weight loss drugs can help employers cut health care costs, study says

Employers may experience reduced healthcare expenses over time by investing in costly GLP-1 medications, as a comprehensive study of insurance claims indicates savings become appar...

Read Full Article →